Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 1

Хроническая сердечная недостаточность с сохранной фракцией выброса у лиц пожилого и старческого возраста
Е.С. Тарас, А.Н. Атаканова, А.Д. Эрлих, О.А. Кисляк

Список литературы

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016 Jul;37(27):2129-200.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation 2002 Dec;106(24):3068-72.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted county, Minnesota, in 1991. Circulation 1998 Nov;98(21):2282-9.
4. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA 2006 Nov;296(18):2209-16.
5. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A; EPICA Investigations. Prevalence of chronic heart failure in southwestern Europe: the EPICA study. European Journal of Heart Failure 2002 Aug;4(4):531-9.
6. van der Velden J, van der Wall EE, Paulus WJ. Heart failure with preserved ejection fraction: current status and challenges for the future. Netherlands Heart Journal 2016 Apr;24(4):225-6.
7. Altei H, Pehlivanoglu S. Heart failure with preserved ejection fraction, cardiomyopathies-types and treatment. IbtechOpen. Published 2017 Apr 12. Available from: https://www.intechopen.com/books/cardiomyopathies-types-and-treatments/heart-failure-with-preserved-ejection-fraction Accessed 2020 Jun 08.
8. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. Journal of the American College of Cardiology 2014 Apr;63(25 Pt A):2817-27.
9. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017 Jul;136(1):6-19.
10. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WH, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM; National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. JAMA 2018 Nov;320(17):1764-73.
11. Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, Kizer JR, Sarma A, Blaha MJ, Gansevoort RT, Gardin JM, Hillege HJ, Ji F, Kop W, Lau ES, Lee DS, Sadreyev R, van Gilst WH, Wang TJ, Zanni MV, Vasan RS, Allen NB, Psaty BM, van der Harst P, Levy D, Larson M, Shah SJ, de Boer RA, Gottdiener JS, Ho JE. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Failure 2018 Aug;6(8):701-9.
12. Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. The Journals of Gerontology. Series A. Biological Sciences and Medical Sciences 2001 Feb;56(2):M88-96.
13. Joseph SM, Rich MW. Targeting frailty in heart failure. Current Treatment Options in Cardiovascular Medicine 2017 Apr;19(4):31.
14. Carlson C, Merel SE, Yukawa M. Geriatric syndromes and geriatric assessment for the generalist. The Medical Clinics of North America 2015 Mar;99(2):263-79.
15. Newman AB, Gottdiener JS, Mcburnie MA, Hirsch CH, Kop WJ, Tracy R, Walston JD, Fried LP; Cardiovascular Health Study Research Group. Associations of subclinical cardiovascular disease with frailty. The Journals of Gerontology. Series A. Biological Sciences and Medical Sciences 2001 Mar;56(3):M158-66.
16. Vitale C, Spoletini I, Rosano GMC. Frailty in heart failure: implications for management. Cardiac Failure Review 2018 Aug;4(2):104-6.
17. Rockwood K, Hogan DB, MacKnight C. Conceptualisation and measurement of frailty in elderly people. Drugs & Aging 2001 Oct;17(4):295-302.
18. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. Journal of the American College of Cardiology 2003 Oct;42(7):1226-33.
19. Imazio M, Cotroneo A, Gaschino G, Chinaglia A, Gareri P, Lacava R, Voci TD, Trinchero R. Management of heart failure in elderly people. International Journal of Clinical Practice 2008 Feb;62(2):270-80.
20. Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clinics in Geriatric Medicine 2000 Aug;16(3):445-56.
21. Pierce B, Tschöpe C, de Boer AR, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam SP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal 2019 Oct;40(40):3297-317.
22. Vaes B, de Ruijter W, Gussekloo J, Degryse J. The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review. Age and Ageing 2009 Nov;38(6):655-62.
23. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association 2009. Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. Journal of the American College of Cardiology 2009 Apr;53(15):e1-90.
24. Beckett NS, Peters R, FletcherAE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. The New England Journal of Medicine 2008 May;358(18):1887-98.
25. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European Heart Journal 2006 Apr;27(8):949-53.
26. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA 2001 May;285(18):2370-5.
27. Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases 2005 May-Jun;47(6):357-66.
28. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 Sep;362(9386):777-81.
29. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 Oct;27(19):2338-45.
30. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine 2008 Dec;359(23):2456-67.
31. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis E, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine 2014 Apr;370(15):1383-92.
32. Pfeffer MA, Clagget B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patents and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 2015 Jan;131(1):34-42.
33. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B. Rationale and design of the ‘Aldosterone Receptor Blockade in Diastolic Heart Failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure 2010 Aug;12(8):874-82.
34. Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB, Meyer M. Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Network Open 2019 Dec;2(12):e1916598.
35. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. The Lancet 2012 Oct;380(9851):1387-95.
36. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong JJ, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O’Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation. Heart Failure 2018 Jul;11(7):e004962.
37. Aggarwal M, Bozkurt B, Panjrath G, Aggarwal B, Ostfeld RJ, Barnard ND, Gaggin H, Freeman AM, Allen K, Madan S, Massera D, Litwin SE; American College of Cardiology’s Nutrition and Lifestyle Committee of the Prevention of Cardiovascular Disease Council. Lifestyle modifications for preventing and treating heart failure. Journal of the American College of Cardiology 2018 Nov;72(19):2391-405.
38. Стародубов В.И., Дворников А.С., Шевченко А.Г., Лопаков К.В. Перспективы более раннего выявления заболеваний по результатам опроса пользователей интернета об их отношении к профилактике. Социальные аспекты здоровья населения 2011;19(3):2.
39. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction : a randomized, controlled, single-blind trial. Circulation. Heart Failure 2010 Nov;3(6):659-67.

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016 Jul;37(27):2129-200.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation 2002 Dec;106(24):3068-72.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted county, Minnesota, in 1991. Circulation 1998 Nov;98(21):2282-9.
4. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA 2006 Nov;296(18):2209-16.
5. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A; EPICA Investigations. Prevalence of chronic heart failure in southwestern Europe: the EPICA study. European Journal of Heart Failure 2002 Aug;4(4):531-9.
6. van der Velden J, van der Wall EE, Paulus WJ. Heart failure with preserved ejection fraction: current status and challenges for the future. Netherlands Heart Journal 2016 Apr;24(4):225-6.
7. Altei H, Pehlivanoglu S. Heart failure with preserved ejection fraction, cardiomyopathies-types and treatment. IbtechOpen. Published 2017 April 12. Available from: https://www.intechopen.com/books/cardiomyopathies-types-and-treatments/heart-failure-with-preserved-ejection-fraction Accessed 2020 Jun 08.
8. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. Journal of the American College of Cardiology 2014 Apr;63(25 Pt A):2817-27.
9. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017 Jul;136(1):6-19.
10. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WH, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM; National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. JAMA 2018 Nov;320(17):1764-73.
11. Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, Kizer JR, Sarma A, Blaha MJ, Gansevoort RT, Gardin JM, Hillege HJ, Ji F, Kop W, Lau ES, Lee DS, Sadreyev R, van Gilst WH, Wang TJ, Zanni MV, Vasan RS, Allen NB, Psaty BM, van der Harst P, Levy D, Larson M, Shah SJ, de Boer RA, Gottdiener JS, Ho JE. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Failure 2018 Aug;6(8):701-9.
12. Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. The Journals of Gerontology. Series A. Biological Sciences and Medical Sciences 2001 Feb;56(2):M88-96.
13. Joseph SM, Rich MW. Targeting frailty in heart failure. Current Treatment Options in Cardiovascular Medicine 2017 Apr;19(4):31.
14. Carlson C, Merel SE, Yukawa M. Geriatric syndromes and geriatric assessment for the generalist. The Medical Clinics of North America 2015 Mar;99(2):263-79.
15. Newman AB, Gottdiener JS, Mcburnie MA, Hirsch CH, Kop WJ, Tracy R, Walston JD, Fried LP; Cardiovascular Health Study Research Group. Associations of subclinical cardiovascular disease with frailty. The Journals of Gerontology. Series A. Biological Sciences and Medical Sciences 2001 Mar;56(3):M158-66.
16. Vitale C, Spoletini I, Rosano GMC. Frailty in heart failure: implications for management. Cardiac Failure Review 2018 Aug;4(2):104-6.
17. Rockwood K, Hogan DB, MacKnight C. Conceptualisation and measurement of frailty in elderly people. Drugs & Aging 2001 Oct;17(4):295-302.
18. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. Journal of the American College of Cardiology 2003 Oct;42(7):1226-33.
19. Imazio M, Cotroneo A, Gaschino G, Chinaglia A, Gareri P, Lacava R, Voci TD, Trinchero R. Management of heart failure in elderly people. International Journal of Clinical Practice 2008 Feb;62(2):270-80.
20. Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clinics in Geriatric Medicine 2000 Aug;16(3):445-56.
21. Pierce B, Tschöpe C, de Boer AR, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam SP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal 2019 Oct;40(40):3297-317.
22. Vaes B, de Ruijter W, Gussekloo J, Degryse J. The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review. Age and Ageing 2009 Nov;38(6):655-62.
23. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association 2009. Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. Journal of the American College of Cardiology 2009 Apr;53(15):e1-90.
24. Beckett NS, Peters R, FletcherAE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. The New England Journal of Medicine 2008 May;358(18):1887-98.
25. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European Heart Journal 2006 Apr;27(8):949-53.
26. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA 2001 May;285(18):2370-5.
27. Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases 2005 May-Jun;47(6):357-66.
28. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 Sep;362(9386):777-81.
29. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 Oct;27(19):2338-45.
30. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine 2008 Dec;359(23):2456-67.
31. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis E, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine 2014 Apr;370(15):1383-92.
32. Pfeffer MA, Clagget B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patents and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 2015 Jan;131(1):34-42.
33. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B. Rationale and design of the ‘Aldosterone Receptor Blockade in Diastolic Heart Failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure 2010 Aug;12(8):874-82.
34. Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB, Meyer M. Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Network Open 2019 Dec;2(12):e1916598.
35. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. The Lancet 2012 Oct;380(9851):1387-95.
36. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong JJ, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O’Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation. Heart Failure 2018 Jul;11(7):e004962.
37. Aggarwal M, Bozkurt B, Panjrath G, Aggarwal B, Ostfeld RJ, Barnard ND, Gaggin H, Freeman AM, Allen K, Madan S, Massera D, Litwin SE; American College of Cardiology’s Nutrition and Lifestyle Committee of the Prevention of Cardiovascular Disease Council. Lifestyle modifications for preventing and treating heart failure. Journal of the American College of Cardiology 2018 Nov;72(19):2391-405.
38. Starodubov VI, Dvornikov AS, Shevchenko AG, Lopakov KV. Prospects for earlier detection of diseases in Russia based on results of a questionnaire of Internet users about their attitude to prevention. Social Aspects of Population Health 2011;19(3):2 (In Russian).
39. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circulation. Heart Failure 2010 Nov;3(6):659-67.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]